Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06612268 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
A Phase 3 study of Sickle Cell Disease, sponsored by Novo Nordisk A/S.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 408
- Enrollment target
- 20
- Study locations
NCT06612268 is a Phase 3 study of Sickle Cell Disease that is actively recruiting participants, run by Novo Nordisk A/S. The registered enrollment target is 408 participants, above the 291-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (40% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT06612268, a Phase 3 study of Sickle Cell Disease, is actively recruiting participants, sponsored by Novo Nordisk A/S.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 408 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is conducted to confirm whether etavopivat works well at reducing the number of Vaso-occlusive crisis VOCs (sickle cell pain crises) caused by obstructions in blood vessels in adults and adolescents living with sickle cell disease. The study will also evaluate how well etavopivat can reduce the damage to different organs, improve your exercise tolerance and reduce fatigue in people with sickle cell disease.The participants will either get etavopivat or placebo. Which treatment the participants will get is decided by chance. Etavopivat is a new medicine and is currently being tested in other studies in addition to this one. The study will last for about 2 years.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Etavopivat
Study Locations (20)
California
- Children's Hospital Los Angeles - Endocrinology - Los Angeles
- UCLA Health - Los Angeles
- Valley Children's Hospital - Madera
- University Of California Irvine - Orange
- Stanford University_Palo Alto - Palo Alto
- Harbor-UCLA Medical Center - Torrance
Alabama
- Uni of Alabama at Birmingham - Birmingham
- Univer South Alabama Ped/Onc - Mobile
District of Columbia
- Childrens National Medical Ctr - Washington D.C.
- MedStar Hlth Res Institute - Washington D.C.
Illinois
- Childrens Hospital of Chicago - Chicago
- Univer Of Illinois at Chicago - Chicago
Arizona
- Phoenix Children's Hsptl - Phoenix
Arkansas
- Arkansas Children's Hospital - Little Rock
Colorado
- Clinical and Transl Res Center - Aurora
Delaware
- Nemours/AI duPont Hosp-Chld - Wilmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 408 participants |
| Start Date | 2025-02-17 |
| Est. Completion | 2029-03-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06612268
The ClinicalTrials.gov registry entry for NCT06612268 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 408 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 291-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (40% higher). The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sickle Cell Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06612268 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Alabama, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT06612268 about?
NCT06612268 is a clinical study titled "A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease". This study is conducted to confirm whether etavopivat works well at reducing the number of Vaso-occlusive crisis VOCs (sickle cell pain crises) caused by obstructions in blood vessels in adults and adolescents living with sickle cell disease. The study will also evaluate how well etavopivat can redu...
What is the current status of trial NCT06612268?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 408 participants. The study started on 2025-02-17. Estimated completion is 2029-03-12.
What conditions does trial NCT06612268 study?
This clinical trial studies the following conditions: Sickle Cell Disease.
What interventions are being tested in trial NCT06612268?
The interventions under investigation include: Placebo (DRUG), Etavopivat (DRUG).
Who is sponsoring clinical trial NCT06612268?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06612268 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
RECRUITING · Phase 3
-
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
RECRUITING · Phase 3
-
The Efficacy and Safety of Rilzabrutinib in Patients Aged 10 to 65 Years With Sickle-cell Disease
RECRUITING · Phase 3
-
Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease
RECRUITING · Phase 3
-
Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
RECRUITING · Phase 3
-
A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.